BACKGROUND: To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS: We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametric magnetic resonance imaging (mpMRI) and targeted and/or template biopsy. IRE was delivered under transrectal ultrasound guidance with two to six electrodes positioned transperineally within the cancer lesion. Complications were recorded and scored accordingly to the NCI Common Terminology Criteria for Adverse Events; the functional outcome was physician reported in all patients with at least 6 months follow-up. A contrast-enhanced MRI 1 week after the procedure was carried out to assess treatment effect with a further mpMRI at 6 months to rule out evidence of residual visible cancer. RESULTS: Overall, 34 patients with a mean age of 65 years (s.d. = ± 6) and a median PSA of 6.1 ng ml − 1 (interquartile range (IQR) = 4.3-7.7) were included. Nine (26%), 24 (71%) and 1 (3%) men had low, intermediate and high risk disease, respectively (D'Amico criteria). After a median follow-up of 6 months (range 1-24), 12 grade 1 and 10 grade 2 complications occurred. No patient had grade 4/ = 3 complication. From a functional point of view, 100% (24/24) patients were continent and potency was preserved in 95% (19/20) men potent before treatment. The volume of ablation was a median 12 ml (IQR = 5.6-14.5 ml) with the median PSA after 6 months of 3.4 ng ml − 1 (IQR =1.9-4.8 ng ml − 1 ). MpMRI showed suspicious residual disease in six patients, of whom four (17%) underwent another form of local treatment. CONCLUSIONS: Focal IRE has a low toxicity profile with encouraging genito-urinary functional outcomes. Further prospective development studies are needed to confirm the functional outcomes and to explore the oncological potential.
INTRODUCTION
The therapeutic ratio-benefit to harms-of standard therapies used in the treatment of localised prostate cancer is low. 1 As a result, much clinical and research effort has centred on reducing the side effects of current radical therapies. Focal therapy has emerged as one such strategy that might reduce harms whilst retaining the benefit of cancer control.
Focal therapy, in its various forms, has been evaluated in early prospective proof of concept studies and is currently fully recruited to a randomised controlled trial in Europe. [2] [3] [4] Whilst these studies used high intensity focused ultrasound and vascular targeted therapy, respectively, other studies/case series have evaluated cryotherapy and thermal laser. [5] [6] [7] [8] The results of all these reports have been summarised in a recent systematic review 9 showing that incontinence is 0-5%, impotence is 0-46% and disease control using biopsies is 77-96.3%. Early toxicity from these various ablative modalities can be high with recto-urethral fistula reported in up to 2.4% patients.
Irreversible electroporation (IRE) is a non-thermal energy source that is being used in the USA and in Europe by interventional radiologists in liver, kidney and pancreas in a primary, salvage and palliative role. [10] [11] [12] [13] Although it is approved and being used in both jurisdictions in the treatment of prostate cancer, only few case reports of its use in this role exist in the urological literature. 14, 15 This report combines the work of two groups working independently who adopted the IRE technology early and applied it very selectively in a real practice clinical setting with careful institutional audit of results.
MATERIALS AND METHODS Design/Population
This is a two-centre (Princess Grace Hospital in London/UK and St.Vincent's Prostate Cancer Centre, Sydney/Australia) retrospective analysis of men with localised prostate cancer treated with IRE. It represents the two learning curves within these two institutions (August 2011 to August 2013). Internal review board exemption was granted.
As part of the local approach for accurately characterising treatmentnaïve patients interested in tissue-preserving approaches, all men underwent multi-parametric magentic resonance imaging (1.5 or 3 T mpMRI with a pelvic coil; T2-weighted/dynamic-contrast enhanced/diffusion-weighted sequences; the OsiriX Imaging Software (Pixmeo SARL, Bernex, Switzerland) was used for post-acquisition processing and reporting) and histological verification of suspicious areas by targeted and/or transperineal template mapping biopsy. All patients in this cohort had one MRI visible lesion concordant with histological findings showing clinically significant prostate cancer in this area. Any Gleason pattern 4/ = 4 and/or cancer core length 4/ = 4 mm was considered clinically significant cancer. Informed consent was obtained from all patients after thoroughly discussing the potential risks along with the possible advantages of this new technology. Procedure IRE was delivered using the Nanoknife System (AngioDynamics, Queensbury, NY, USA). The Nanoknife System is composed of a generator, which deploys low-energy direct current that leads to cell death by the formation of nanopores within the cell membrane rather than heating effect. 16, 17 According to the treatment strategy and the characteristics of the area to target, a certain number of needles are positioned to delineate the treatment area. Maximum electrode exposure length per needle is 2 cm, and the distance between two needles should not exceed 2 cm again; therefore, the number of needles was proportional to the treatment area. Once, the electrodes have been inserted, the distances between each two electrodes are measured on the transrectal ultrasound axial view. The device was set to deliver 90 pulses with a pulse length at 70 μs. The treatment to deliver was then automatically calculated by the system on the basis of the number of needles employed, the distances between them and the active electrode length used to obtain an optimal electrical field between 20 and 40 A, which seems to cause complete ablation within the target area with no thermal damage. 16 Before delivering all the 90 pulses, a 'test pulse' at 10 pulses was delivered to verify the actual electrical field in the tissue. Indeed, current above the upper threshold of 40 A may cause out-field treatment and heating damage, whereas current below the lower limit of 20 A may lead to under-treatment. Therefore, if the current was in this range, the remaining 80 pulses were delivered, whereas in the opposite case, the treatment planning was modified. Of note, the system calculates the current separately between every two needles, hence it is possible to modify selectively the treatment only in the area needed without affecting the remaining parameters.
Electrodes were positioned at the margin of the lesion under transrectal ultrasound guidance using a brachytherapy stepper and grid set-up ( Figure 1 ). As this was part of the learning curve of both institutions, it was not possible to standardise the intervention. Men treated in the early part of the experience had small volume lesions, and were treated cautiously with two electrodes into the target area. As experience accumulated, in an iterative manner, targets of greater volume were targeted with four to six needles. Because the maximum electrode exposure length is 2 cm, if a lesion was longer than this in the 'Z' plane of the prostate, a pull-back and second treatment was used. The target volume was defined by mpMRI and histopathology with a safety margin of 3-5 mm.
Intravenous cefuroxime and gentamicin antibiotics were administered at induction; patients were under general anaesthesia with deep muscle paralysis using pancuronium bromide. Continuous perioperative electrocardiographic monitoring with ECG was maintained. Urinary catheters were managed differently in the two centres. The Princess Grace Hospital cohort had either a urethral or a suprapubic catheter placed at the time of the procedure, and a first attempt to remove the catheter was performed between 3 and 5 days after treatment. At St. Vincent's Prostate Cancer Centre, a urethral catheter was inserted for the procedure, and removed at the end of the procedure unless the target lesion abutted the urethra.
Follow-up
Early contrast-enhanced MRI was obtained after 1 week to evaluate the local effect of the treatment, and to rule out rectal damage, which might indicate a recto-urethral fistula. On this scan, the ablation area was calculated by planimetry. Patients were then followed up by clinical visits with serum PSA levels every 3 months. Also, a late mpMRI was performed 6 months after the procedure, and then once a year. All MRIs were reported by one experienced radiologist per centre using the Likert scale to define the likelihood of residual disease (1 = extremely unlikely; 2 = unlikely; 3 = equivocal; 4 = likely; 5 = extremely likely). Residual disease was evaluated by comparing post-IRE MR images with pre-operative scans in which the treated lesion was visible. Residual cancer was suspected in case of an early enhancing focus on dynamic contrast sequence and residual restricted diffusion in the treatment area. In this study, values 3-5 were considered suspicious for residual cancer. During the perioperative period and the follow-up, complications were reported per type, and retrospectively scored according to the NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE). Genito-urinary outcome is only reported for patients who were potent and/or continent before treatment, and with at least 6 months follow-up. Potency and urinary continence were physician-evaluated on the basis of patient-reported ability to have erections sufficient for penetrative sexual intercourse and no pad use, respectively. The use of pre-operative and post-operative PDE-5 inhibitors was not systematically recorded.
Statistics
Continuous variables are given using the mean ± standard deviation (s.d.), or using the median and the overall/ interquartile range (IQR) according to their distribution; categorical variables are given using frequencies and percentages. Each patient was censored up to the time of last follow-up. All analyses were performed using SPSS version 20.0 (IBM, Armonk, NY, USA).
RESULTS
Overall, 34 patients were treated using primary focal IRE across the two centres, Princess Grace Hospital (n = 20) and St. Vincent Prostate Cancer Centre (n = 14). Basic patients' characteristics and histological findings are summarised in Table 1 . Mean age was 65 ± 6 years; median PSA was 6.1 ng ml − 1 (IQR = 4.3-7.7). A few men (n = 2; 6%) had only transperineal targeted biopsy, whereas the majority (n = 32; 94%) had template prostate mapping with Table 2 summarises the perioperative outcomes. In each patient, a median of four probes were employed, the median operative time from insertion of needles to completion was 27 min (range 11-55). Thirty-two patients (94%) were discharged the same evening of the day of the procedure and two stayed overnight. In nine (26%), no catheter was inserted during the procedure, whereas in the remaining either a suprapubic (n = 9; 26%) or an urethral catheter (n = 16; 48%) was inserted. Median catheterisation length was 3 days (range = 0-9).
Toxicity
Genito-urinary toxicity is displayed in Table 3 ; overall adverse events stratified by the NCI-CTCAE grade are displayed in Table 4 . All complications were grade 1 or 2, and no severe adverse event occurred. No patients had a recto-urethral fistula, and none had a urethral stricture. Non genito-urinary adverse events occurred in four men. One patient had self-resolving per-operative tachycardia requiring 24-hour inpatient surveillance with no additional intervention; one patient stayed over-night for 'social reasons'; and two patients needed prolonged wound dressing at the site of the suprapubic catheter following catheter removal.
Successful catheter withdrawal at first attempt was achieved in 32 patients (94%). Some patients had either dysuria (n = 6; 18%), or debris and/or haematuria (n = 5; 15%) at one of the follow-up visits. Five patients (15%) developed uncomplicated urinary tract infection that were all managed with oral antibiotics.
Functional outcome
Median follow-up was 6 months (range = 1-24) with 24 patients (71%) having a follow-up of at least 6 months (Table 5 ). Potency was preserved in 95% (19/20) potent men before treatment, whereas all men continent before treatment were still continent (no pad usage) after treatment (24/24) . No rectal dysfunction was recorded; however, this was probably not specifically and systematically investigated at follow-up.
Early disease control On early MRI, the ablation area was estimated to be a median of 12 ml (IQR = 5.6-14.5 ml) ( Figure 2 ). Median PSA at 6 months was 3.2 ng ml − 1 (IQR = 1.9-4.8). In the follow-up period, mpMRI showed suspicious residual disease in six patients. Two of these patients remain on surveillance because the PSA dropped significantly from pre-operative values. Four patients (17%) underwent a secondary treatment. Three patients had a secondary focal ablation in the same area, one using IRE and two using high intensity focused ultrasound. Only one patient had histological verification of failure with transperineal targeted biopsy detecting residual Gleason 3+4. He chose to undergo radical prostatectomy, which showed residual disease stage T2c Gleason 3+4. Unfortunately, the procedure was performed in another institution, and no zonal analysis was reported; therefore, it was not possible to determine the local effect of IRE in the treated area. Greater follow-up is required to determine the success of this further therapy. No patient died, had metastasis or switched to systemic treatment.
DISCUSSION
This study shows that focal IRE seems to be well tolerated in a heterogeneous group of patients across two centres. The genitourinary outcomes, in terms both of erectile function and urinary continence, appear particularly encouraging. Longer follow-up in a protocol-driven study is needed to derive any conclusion with respect to the cancer-control outcomes.
Limitations
Before discussing our findings, it is important to acknowledge the limitations of this study. First, the functional outcomes are reported on the basis of physician-reported measures, so may be overestimated. We are currently recruiting to a prospective ethics committee approved registered trial in the UK with embedded patient questionnaires to overcome this shortcoming. 18 Second, both the short follow-up and the absence of systematic histological verification of complete ablation in the treatment area do not allow us to draw any conclusion with respect to the efficacy of IRE in prostate cancer. In fact, as PSA kinetics alone are not specific enough to predict recurrence after focal treatment, we also used postoperative mpMRI to determine local failure. Although this tool seems promising in detecting recurrent disease after tissuepreserving treatment, it has not been validated yet in IRE. [19] [20] [21] Third, heterogeneity clearly exists in terms of patients' characteristics, selection of patients and standard operating procedures. All patients underwent mpMRI for eligibility, but the histological verification modality ranged from a few targeted biopsies of suspicious areas to full prostate mapping with additional samples derived from MRI targets according to physicians' choice and preoperative mpMRI results. Although this might have hindered the selection of patients, in both centres, the diagnostic accuracy of the mpMRI protocol has been previously verified and negative predictive value for ruling out significant disease was at 90--95%. 22, 23 Fourth, the retrospective nature of the study along with the small sample size represent additional limitations.
Clinical Implications
A recent systematic review of ablation modalities used for focal treatment of prostate cancer has shown that various modalities have been already used in selected patients with variable results. 9 However, IRE might have potential advantages over these. First, the non-thermal nature of the tissue damage seems to lead to very tight cell-kill zones in animal experiments and this might have advantages in prostate cancer focal therapy by allowing greater control over ablation of the target area. 24 Further, the local ablation should not be hindered by the so-called 'heat sink' effect that can limit the efficacy of thermal ablation. Another potential characteristic of IRE is the possibility of tissue selectivity. Animal studies have shown that when an appropriate electrical field is employed, complete destruction of the target area can be achieved without damaging the collagenous structures-such as nerves, vessels and the urethra. In randomised controlled studies in which IRE was delivered to 30 rat sciatic nerves, although there was a decrease in nerve conductivity immediately after the procedure, after seven weeks, electrophysiological, functional and histological findings showed that the nerves had fully recovered. 25 Similar findings were demonstrated in focal IRE of canine prostates, in which the urethra and the neurovascular bundles were not affected histologically. 24, 26 Finally, the procedure time is considerably shorter compared with other focal treatments. This is because of the fact that once the needles are positioned, the exposure time for a complete ablation is less than 5 min per lesion.
The interesting finding in this study remains the low toxicity, with no severe complication after treatment, and no recto-urethral fistulae. If we compare these results with the toxicity and the functional outcomes of current technologies used in focal therapy in prostate cancer, IRE is certainly encouraging. 9 This low toxicity is probably related to the inner characteristics of the energy discussed above.
From a disease control point of view, it is difficult to draw any definitive conclusions. This series should be regarded as the first step in the investigation of IRE in clinical studies. Recently, guidelines have been issued to guide researchers on how to assess new technologies in surgery. [27] [28] [29] This framework includes an initial phase of liberal, but safe clinical assessment by experts in the field. 27 Experience gained through this phase has allowed standardisation of the technique to take place through an iterative process of modifications to the technique. As a result, recruitment to a prospective development study evaluating disease control outcomes with post-treatment biopsies as well as prospective patient-reported outcomes on genitourinary and rectal function has just begun. 18 Focal IRE may enhance the perioperative outcome and the functional preservation in patients undergoing prostate cancer focal treatment. However, rigorous prospective studies with systematic assessment of the functional and of the oncological outcomes are needed to move forward in the evaluation of this new technology.
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